Infectious Diseases Space Wide Open For Partnering Beyond Hep C, Conference Finds
This article was originally published in The Pink Sheet Daily
The recent spotlight on hepatitis C doesn't mean that's the only hot area in infectious diseases for deals.
You may also be interested in...
SEOUL - South Korea's CrystalGenomics recently wrapped up the second-round of Phase I clinical trials for its antibiotic candidate CG400549 in Europe
If its $2.4 billion bid to buy Crucell N.V. succeeds, Johnson & Johnson will have managed to take a quick leap forward in the vaccines space, going overnight from a non-player to the number six company in the space, behind market leaders GlaxoSmithKline, Merck, Pfizer, Sanofi-Aventis and Novartis.
"Without question, hepatitis C is the number one exciting area in infectious diseases," insists Paul Zhang, a principal in the health care advisory group Easton Associates, LLC.